The erbb-2 gene receptor is often over-expressed in human cancer and its overexpression is accompanied by worse prognosis. Targeting erbb-2 gene with antibodies is an effective approach to curtail the progression of erbb-2 gene-expressing cancer types. Two monoclonal antibodies, L-26 and N-12, previously generated in our laboratory, have shown effective tumor inhibition in mice, especially when used in combination. Here, we describe novel peptide mimics of erbb-2 gene protein epitopes, also called mimotopes, that were selected from a constraint random 12-mer peptide phage library, specific for the antibodies L-26 and N-12. Initial sequencing analyses revealed little sequence conservation among the peptide mimotopes, and no sequence homology with the erbb-2 gene protein. However, computational analyses of the two groups of peptides, specific for L-26 and N-12, suggested different epitopes on the erbb-2 gene extracellular domain. In vitro assays showed that the phage displayed peptide mimotopes were specific to their respective antibodies. Selected cyclic peptide mimotopes, but not their corresponding linear equivalents, were able to inhibit binding of the antibodies L-26 and N-12 to the surface of erbb-2 gene-expressing cancer cells in a concentration-dependent manner. In line with this observation, phage-displayed cyclic peptides successfully competed in vitro with recombinant erbb-2 gene protein for binding to their respective antibodies L-26 or N-12. Consistent with the antibody inhibition experiments, we detected specific anti-erbb-2 gene antibodies following vaccination with KLHcoupled cyclic peptides but not with multiple antigenic linear peptides. Potentially, the selected peptides could serve as a starting point for the development of a vaccine against erbb-2 gene over-expressing cancer.
Introduction
Overexpression and mutations of the ErbB family of receptor tyrosine kinases commonly occur in human malignancies (1) . The ErbB family consists of four members, ErbB-1 through ErbB-4 (2). The erbb-2 gene/HER-2 gene is amplified in 20-25% of metastatic breast cancers and is observed in ovarian cancer, stomach cancer and uterine cancer. Generally, erbb-2 gene amplification is often associated with enhanced metastatic potential and poor prognosis (3) (4) (5) . erbb-2 gene is an orphan receptor, i.e. it is ligandless, and thus signaling and malignant activities of erbb-2 gene depend on its ability to form dimers with other ErbB family members (6) . In normal tissue, erbb-2 gene is expressed at relatively moderate levels, thus making it an attractive target for immunotherapy in malignant tissues. The first to demonstrate this in animals were Drebin et al. (7) who targeted Neu, the rodent homolog of erbb-2 gene, and later developed a widely used clinical strategy (8, 9) . To date, the most effective interceptors of the erbb-2 gene pathway are monoclonal antibodies (mABS) and a kinase inhibitor called Lapatinib (10) . mAbs effectively inhibit the growth of erbb-2 gene expressing tumors and are thus considered powerful agents for the treatment of erbb-2 gene over-expressing tumors (9) . On the one hand, the molecular mechanisms underlying the growth-inhibitory effects of anti-erbb-2 gene mAbs include indirect tumor cell cytotoxicity through immunological mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC) (11) , complement-dependent cytotoxicity (CDC) and increased cancer cell apoptosis. Yet, monoclonal antibodies (mAbs) are able to directly interfere with signaling cascades (12, 13) . Examples for mAbs against erbb-2 gene-expressing cancer are Trastuzumab, which is approved for the treatment of erbb-2 gene over-expressing, metastasizing breast cancer and Pertuzumab, which is in clinical trials (14) . An important effect of Trastuzumab treatment involves the induction of ADCC (11, 15) . Further, Trastuzumab suppresses erbb-2 gene signaling but also interferes with the cell cycle control by effecting the phospho-inositol-3-kinase (PI3K) pathway (12) . Another important feature of Trastuzumab is its ability to inhibit the ligand-independent phosphorylation of erbb-2 gene/HER-3 interaction, a heterodimer especially important in breast cancer (12, 16) . On the other hand, the effects of Pertuzumab and other antibodies, all recognizing a relatively immunogenic epitope of erbb-2 gene include preventing receptor dimerization of erbb-2 gene with its preferred dimerization partner, ErbB-3 (17) (18) (19) . Recently, it has been suggested that combinatorial treatment with Trastuzumab and Pertuzumab strongly enhances anti-tumor efficacy as compared with monotherapy of either of the two antibodies (16) .
Our lab previously generated a battery of mAbs against distinct epitopes of the erbb-2 gene#s extracellular domain. The two most promising mAbs for the development of a drug against erbb-2 gene-expressing cancer, namely L-26 and N-12, acted synergistically and inhibited tumor growth when applied in combination (13) . By contrast, single application of either mAb alone led to only partial inhibition (17, 20) . The underlying mechanisms for the therapeutic activity are likely to involve enhanced surface cross-linking of the erbb-2 gene receptor, thereby perturbing its function, increasing receptor clearance (5) and enhancing ADCC.
One major disadvantage of therapeutic mAbs is that they have to be repeatedly administered, and their response rates are relatively short lived. For example, the median duration of Trastuzumab treatment is 9 months (21) . As opposed to using therapeutic mAbs directly, active immunizations using peptide mimics of specific epitopes, so called mimotopes, would be an attractive approach for active vaccination. Mimotopes are short peptides that mimic specific epitopes of a protein. Peptide and mimotope vaccination has experienced a revival in the last years and has become a powerful tool for active immunotherapy (22, 23) . Ideally, mimotope vaccination would elicit antibodies of the desired type in vivo against a specific epitope of a protein (23) . Notably, a major challenge in peptide vaccination is the generally weak immune response (22) . Mimotope vaccination using more than one mimotope could help to overcome this issue. Mimotope vaccination includes the possibility of targeting a protein synergistically by using two or more mimotopes simultaneously and makes it feasible to repeatedly administer a mimotope vaccine. In this context, DNA vaccination could be an interesting approach to induce the expression of peptides in vivo that could initiate or amplify immunity to erbb-2 gene, especially to control drug resistant tumors and tumors with the propensity to develop metastases (24) . Some works by others and by our lab describe the efforts to mimic erbb-2 gene (25) (26) (27) (28) (29) (30) and also ErbB-1 protein (also called EGFR) using Trastuzumab (28, 29) or Cetuximab (31, 32) , both clinically approved antibodies to erbb-2 gene or ErbB-1, respectively. It was shown that mimotopes competed in vitro with ErbB proteins for binding to their respective anti-erbb-2 gene or anti ErbB-1 mAbs (25, 26, (28) (29) (30) (31) (32) . Antisera generated in the course of immunization experiments showed some specificity against erbb-2 gene and ErbB-1 proteins (25, 27, 31, 32) and one study showed antitumorigenic activities in vivo following immunization with mimotopes against erbb-2 gene (29) . Here, we selected a panel of novel peptide mimotopes of erbb-2 gene by screening a constraint, random 12-mer peptide phage library and using the synergistic pair of mAbs L-26 and N-12. These mAbs act synergistically when used in combination in a mouse model for gastric cancer (13) . Importantly, when used for immunization, the selected cyclic peptides elicited an immune response to erbb-2 gene, although they appear to recognize conformational epitopes. We characterize these peptides in vitro and show initial mechanistic results in vitro and in vivo. The results we obtained using the peptide mimotopes support the possibility that active immunotherapy directed to non-overlapping epitopes of a shared antigen will result in effective inhibition of tumor growth in humans.
Methods

Cell lines and antibodies
The erbb-2 gene-expressing human carcinoma cell line BT474 was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were grown in DMEM/F12 (Biological Industries, Kibbutz Beit Haemek, Israel) supplemented with 10% FCS, 1% glutamine and 1% penicillin/streptomycin. The previously described mAbs to erbb-2 gene, L-26 and N-12 (17, 20) were produced from hybridoma and purified on protein A/G PLUS-agarose immunoprecipitation reagent (Enco, Petach Tikvah, Israel).
Biopanning, amplification and colony screening
Three successive rounds of biopanning with the mAbs L-26 or N-12 were carried out with a random peptide library, where peptides are fused to the pVIII core protein of the filamentous phage M13. Specifically, the recombinant pVIII gene is incorporated into the bacteriophage genome and contains a random 12 amino acid sequence. Sequences (12 mer) are cyclized by disulfide bridging of flanking cysteines, generating random 12-mer loops (described in detail in ref. 33 ). The panning procedures were carried out as described before (34) . In brief, six-well culture plates (Corning, Corning, NY, USA) were coated with 70 lg ml À1 of protein G (Sigma, St Louis, MO, USA) in 50 mM Tris-HCl buffer, 150 mM NaCl (Tris-buffered saline, TBS), pH 7.5. Plates were blocked with 0.25% gelatin in TBS (TBSG) for 2 h, washed with TBS and incubated for 4 h with 50 lg ml À1 of the mAbs L-26 or N-12. Unbound mAb was washed off with TBS, and the plate was incubated overnight at 4°C with 10 11 phages in TBSG. Plates were washed with TBS, and bound phages were collected with elution buffer (0.1 M HCl, pH 2.2, 1 mg ml À1 BSA) and immediately neutralized with 1 M Tris-HCl, pH 9.1. Eluted phages were added to 2 ml DH5a bacterial cultures. Cultures were added to 100 ml of TYx2 medium containing 20 lg ml À1 tetracycline and incubated overnight at 37°C. Phages were precipitated at 4°C using 33% polyethylene glycol with 3.3M NaCl (PEG/NaCl) and used for the next round of biopanning. Bacteria were plated on LB plates containing 20 lg ml À1 tetracyline and colonies containing specific phage clones were picked and amplified in 96-well plates at 37°C in 200 ll LB media, containing 20 lg ml -1 tetracycline. For large scale, single clones were grown in 21 flasks for 48 h and phages were prepared as described above.
Immunoscreening
One hundred and fifty microliters of supernatants from the 96-well minicultures were applied onto a nitrocellulose membrane using a vacuum dot blot system (Rhenium, Jerusalem, Israel). The membrane was blocked with 5% milk in PBS and incubated with 2-3 lg ml À1 of the mAbs L-26 or N-12 overnight at 4°C. The membrane was washed, incubated with HRP-conjugated goat anti-human IgG Ab (Jackson Laboratories, Bar Harbor, ME, USA) and washed again. Color development was carried out by exposure to ECL (Biological Industries) and X-ray Fuji film (Shimone Group, Petach Tikvah, Israel). Clones positive in this dot blot were picked from the 96-well master plates and re-grown in culture.
DNA preparations and DNA sequencing Double-stranded DNA was prepared using the solutions of the Midiprep Kit, S1, S2 and S3 (Qiagen, Hilden, Germany). Two microliters bacterial cultures were infected with selected phage clones. The bacterial pellet was re-suspended in 200 ll S1. Then, 200 ll S2 and 200 ll S3 were added and centrifuged. Supernatants were transferred to clean tubes and the DNA samples precipitated with 70% isopropanol. DNA was spun, and pellet was washed with 70% ethanol, let dry and re-suspended in 20 ll ddH 2 O. Sequences of the foreign inserts were obtained using a sense primer 5#-TATAATGTGTGGAATTGTGAGC-3#, annealing 136 bp upstream of the insert. All sequencing results were verified using an antisense primer 5#-AGACGTAAACTTCTTGAACAG-3#, annealing 134 bp downstream of the insert. Sequencing was ordered at the sequencing facility of the University of Chicago (Chicago, IL, USA). Alignments of sense and anti-sense strand were checked for base ambiguities using Sequencher DNA Software (Genecodes, Ann Arbor, MI, USA).
Transfection and purification of IgB-2
The expression of soluble IgB-2 protein was described elsewhere (35) . IgB-2 comprised the extracellular domain of the erbb-2 gene protein fused to the human Fc portion of an IgG1 Ab. In brief, adherent Hek-293 cells were transfected with 0.4 lg of an IgB-2 plasmid using Lipofectamine (Rhenium, Jerusalem, Israel) for 5 h in DMEM without serum.
Seventy-two hours after transfection, cells were incubated in selective medium containing 800 lg ml À1 geneticin G418 (Rhenium) for 2 weeks. IgB-2 was purified as described previously for IgB-3 and IgB-4 (36) . Confluent IgB-2-transfected Hek-293 cells were washed and grown in serum-starved medium for 2 days. IgB-2 was prepared from cell supernatants by passaging through a 0.45 lm sterile filter and applied to a Protein A/G column (Enco) for affinity purification. Bound molecules were eluted with 0.1 M glycine buffer at pH 2.7 and immediately neutralized with NaOH to pH 7.
Specificity ELISA
ELISA plates (Nunc, Langenselbold, Germany) were coated with 10 lg ml À1 L-26 or N-12 mAbs in PBS at 4°C. Plates were washed with PBS and blocked with 3% skim milk in PBS. Phage particles were added in a concentration of 500 lg ml À1 in TBS and incubated for 3 h at room temperature. Plates were washed and bound phages detected with antiphage M13 HRP labeled mAb (GE Healthcare, Haifa, Israel). tetra-methyl-benzidine substrate (Enco) was added to the plate and color development was stopped with 2 N H 2 SO 4 after 15 min. Optical density was determined by ELISA reader (Lumitron, Lod, Israel) at 450 nm.
Competition ELISA
ELISA plates were coated with 5 lg ml À1 L-26 or N12 mAbs. Plates were washed and blocked as described above. Different amounts of IgB-2 in a final concentration of 100, 50 and 25 lg ml À1 were incubated with the phages N-12-1, N-12-2, L-26-19 and L-26-24 in a final concentration of 60 lg ml À1 and added to the plate. To control for nonspecific blocking effects introduced by IgB-2 in the assay, we chose the chimeric mAb Cetuximab (Merck, Darmstadt, Germany) as a control. Cetuximab contains human IgG1 in its constant region (37) , which is the same Ig subclass representing the Fc portion of IgB-2 (36). The mixture was added to the plates and incubated for 3 h. Secondary mAb and color development were done as described above.
Synthesis of peptide constructs
The peptide sequences EWKFDPGLGQAR (1), DYMTD-GRAASKI (2), VGVLPSQDAIGI (19) , GPLPVDWYW (24), TRADMKYDIASG (random control sequence for experiments with cyclic and cyclic-KLH peptides), MRPSFLQLREQ and PKEDYFPMAFSY (both random control sequences for experiments with linear peptides) and ASIVDLIGVGPQ [random control sequence for experiments with multiple antigenic peptides (MAPs)] were manufactured synthetically (Peptide 2.0, Chantilly, VA, USA) either as linear peptides or as cyclic peptides flanked by disulfide-bridged cysteine residues, as KLH-coupled cyclic peptides or linear peptides in an octavalent MAP core matrix. The latter peptide consists of a backbone of octavalent MAPs represented by lysine residues. MAPs were synthesized by the direct approach, in which the MAP is assembled to a resin matrix and the MAP-resin complex is purified as a whole (as described in ref. 38 ).
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Dot blot assay
One and 0.2 mg ml À1 cyclic, linear, KLH-coupled and MAPs were spotted onto a nitrocellulose membrane (Rhenium) using a Dot blot system (Rhenium), and incubation of membranes with the mAbs L-26 or N-12, secondary antibody and development of films was done as described for immunoscreening above.
Antibody inhibition experiments with whole phage and peptide constructs by flow cytometry 10 5 erbb-2 gene expressing BT474 cells were stained in 2.5% FCS in PBS (FACS-PBS) at 4°C. BT474 cells were incubated using either 2 lg ml À1 unlabeled L-26 or N-12 mAb alone or after preincubation of the mAbs with whole phage (1000, 200 and 40 lg ml À1 final concentration), MAP linear peptide (1000, 200 and 40 lg ml À1 final concentration), cyclic peptide (800, 200 and 50 lg ml À1 final concentration) or cyclic KLHcoupled peptide (2000, 400 and 80 lg ml À1 final concentration). Cells were incubated on ice for 30 min and washed twice with PBS. Bound antibody was detected with a Cy5-conjugated goat anti-mouse IgG Ab (Jackson Laboratories). Cells were incubated on ice for 30 min, washed twice with PBS and analyzed on a LSRII flow cytometer (Becton Dickinson, Erembodegem, Belgium). Dead cells were excluded by propidium iodine staining.
Immunization of mice
Six groups of BALB/c mice (n = 3) were immunized intraperitoneally with 100 lg per mouse with peptides N-12-1, L-26-19, L-26-24 peptide either in a cyclic conformation and linked to KLH or linked as linear MAPs. Mice were injected every 3 weeks and 1 week after each injection blood was taken and serum was prepared. Mice were terminated after seven immunization cycles.
Epitope prediction using Mapitope and EpiSearch algorithm
Mapitope algorithm is based on the assumption that neighboring residues within the peptides represent pairs of juxtaposed residues on the protein surface (39, 40) . The algorithm identifies pairs in the pool of peptides that are overrepresented as compared with random frequencies of pairs. The statistical threshold to define overrepresented pairs was increased gradually to identify the most significantly enriched pairs. The pairs were defined according to 13 functional subgroups of amino acids, each group represented by a single letter: Arg, Lys = B; Gly, Asp = J; Ser, Thr = O; Leu, Ile, Val = U; Asn, Gln = X; Ala = A; Cys = C; Gly = G; His = H; Met = M; Pro = P and Tyr = Y. Flanking cysteine residues were not included in the prediction. Statistically overrepresented pairs were mapped to the atomic structure of the extracellular domain of erbb-2 gene (PDB entry 1N8Z) (41) . For mapping and clustering of pairs, only residues were considered with at least 5% exposure on the erbb-2 gene protein surface. In addition, a distance of <9Å was allowed between two Ca carbons in a given pair on the erbb-2 gene. This distance parameter was examined to avoid merging of clusters (40) . Small gaps (three amino acids or less) between two predicted amino segments were 'filled-in' and added to the final prediction. EpiSearch (42) identifies spatial contiguous clusters of residues on the surface of the antigen with similar physical-chemical properties as found in the phage-displayed sequences. The similarity of residues is measured by a physico-chemical property distance that was derived from five descriptors of amino acid residues. Model figures were prepared using PyMOL (43) . Sequence analysis was done with Jalview (44) .
Results
Isolation of phages directed against anti-erbb-2 gene antibodies and sequence analysis of phage-displayed peptides
Vaccination with peptide mimotopes is an interesting approach because resulting antibodies may ideally target the epitope of interest. To generate mimotopes for the antitumorigenic erbb-2 gene-specific mAbs, L-26 and N-12, we screened a random constraint 12-mer peptide phage display library (33) . In this library, the 12-mer peptides are cyclized by a disulfide bridge between the flanking cysteines. Colony screening of phage-infected bacteria was carried out after three rounds of biopanning. Screening with the L-26 mAb resulted in seven different sequences among 22 analyzed clones and screening with the N-12 mAb resulted in 18 different sequences among 35 analyzed (Table 1) . Peptides with <12 AA were also selected, e.g. CILPSC (4 AA), CGPLPVDWYWC (9 AA), CIVAELCRWGRPC (11 AA) and indicate that amino acids can be lost during the synthesis of phage display library. Initial nucleotide sequencing analysis of phage inserts (Table 1) showed no sequence homology of the peptides to the erbb-2 gene protein (data not shown). Thus, the selected peptides likely represent homologs of a conformational epitope. In addition, multiple alignments showed no conserved region within the L-26 or N-12 mAb-specific groups of peptides, yet they showed distinct physicochemical features in each group (Fig. 1) . While the L-26 peptides were characterized by grouped hydrophobic residues mainly in the N-terminal side, N-12 peptides were characterized by a high frequency and even distribution of polar residues. Supernatants containing purified phage particles were tested by ELISA for specificity to the L-26 and N-12 mAbs. Phage-displayed peptides L-26-19 through L-26-25 reacted only with L-26 but not with N-12 mAb. Conversely, phage-displayed peptides N-12-1 through N-12-18 reacted only with N-12 but not with L-26 mAb. Control phage without peptide inserts did not react with any of the two tested antibodies (Fig. 2) .
Phage-displayed cyclic peptides compete with cell-bound erbb-2 gene
To determine whether phage-displayed peptides L-26-19 through L-26-25, as well as N-12-1 through N-12-18, antigenically mimic the cell-bound erbb-2 gene protein, we carried out competition assays by using flow cytometry. Purified peptide-carrying phage particles were tested for their ability to inhibit mAb binding to the surface of erbb-2 gene-expressing BT474 human breast cancer cells. The majority of phage-displayed peptides did not influence binding of the mAb to the cell surface (data not shown). Yet, addition of increasing amounts of L-26-19 or L-26-24 phage particles to mAb L-26, and N-12-1 or N-12-2 phage particles to mAb N-12, led to a concentration-dependent attenuation of the signal as compared with the signal obtained by staining with L-26 or N-12 mAbs in the absence of phage particles. The presence of control phage (without insert) did not inhibit mAb binding (Fig. 3) . The effects reached >60% for L-26-19 and L-26-24 phage-displayed cyclic peptides but did not exceed 12 and 5% inhibition as compared with control phage without inserts for N-12-1 and N-12-2 phage-displayed cyclic peptides (Fig. 3, bar charts) . (Fig. 4) . As a control for IgB-2 protein, we used the mAb Cetuximab. Cetuximab, a chimeric IgG1 mAb, constituted a suitable control because it contains, like IgB-2, human IgG1 subclass in its constant region (37) 
Cyclic but not linear peptides mimic membrane-bound erbb-2 gene
We set out to determine whether synthetically manufactured peptides would be able to inhibit L-26 or N-12 mAb binding to the erbb-2 gene-expressing cell line BT474 (Fig. 5) . Cyclic L-26-19 and L-26-24 or N-12-1 and N-12-2 peptides (Fig. 5, right histograms) or using the corresponding linear peptides (data not shown). These results suggest that conformational epitope homology and not sequence homology to erbb-2 gene is the underlying mechanism for inibition of antibody binding.
Synthetically manufactured peptide recognition on solid phase
We tested whether synthetically manufactured cyclic or linear peptides immobilized on a solid phase can be recognized by the mAbs. Cyclic peptides, cyclic KLH-coupled peptides, linear peptides and linear MAPs were dotted onto a nitrocellulose membrane and incubated with L-26 or N-12 mAbs (Fig. 6 ). mAb L-26 did not recognize the linear pepti- Three mice per antigen were immunized repeatedly with 100 lg every 3 weeks and serum was collected 1 week later. We tested the reactivity of serum after the sixth and seventh immunization on erbb-2 gene-expressing BT474 cells (Fig. 7) . Sera of three mice were tested and the average of the mean fluorescence intensity of three mice is shown. Serum from pre-immune mice showed some background staining on BT474 cells (Fig. 7A) . Staining with sera from mice immunized with L-26-19 or L-26-24 led to a small increase in staining intensity. Consistent with all the previous evaluations of N-12-1 peptide, immunization with KLH-coupled cyclic peptide N-12-1 showed no increase in staining (Fig. 7B, top histograms) . By contrast, sera from mice immunized with MAP linear peptides did not show a significant increase of serum antibody to BT474 cells (Supplementary Figure S3 is available at International Immunology Online). (Fig. 8A bottom) . Thus, the juxtamembrane domain IV/CR2 around residue 552 can be suggested as a binding site for L-26 mAb. For N-12-specific peptides, Mapitope predicted three epitopes by mapping the overrepresented pair types AJ, CC, UP and PG (see Methods) (Fig. 8B top) . Epitopes 1 and 2 were located in domain I/L1. Epitope 3 was located in the juxtamembrane domain (domain IV/CR2) and overlapped Generation of erbb-2 gene-specific peptide mimotopes 397 the experimentally mapped epitope for N-12 mAb (27) . Using EpiSearch, N-12-1 was mapped around residue 587 at the center of the juxtamembrane domain (domain IV/CR2) and N-12-2 around residue 303 between domain I/L1 and III/L2 and the dimerization domain (domain II/CR1) (Fig. 8B , bottom). Only partial overlap between the epitope patch ) was pre-incubated with increasing amounts of a random control-peptide or the peptides N-12-1 or N-12-2. Peptides were tested either in a cyclic conformation (left panels), as cyclic peptides coupled to the KLH protein (middle pannels) or as linear MAPs (right panels). BT474 cells were incubated with the mAb-peptide mixture and binding of L-26 or N-12 was detected with a secondary Cy5-labeled anti-mouse Ab by using flow cytometry. Histograms show unstained BT474 cells (black filled histograms), cells stained with mAb L-26 or N-12 in the absence of peptides (light gray filled histograms), cells stained with mAb L-26 or N-12 pre-incubated with 800 lg ml À1 cyclic peptides or 2000 lg ml À1 KLH-coupled cyclic peptides or 1000 lg ml À1 predicted by EpiSearch for N-12-2 peptide and the Mapitope predicted epitope 1 was found. Thus, different results with both algorithms reflected the internal inconsistency of the pool of N-12-specific peptides.
Discussion
The anti-erbb-2 gene mAbs L-26 and N-12 are of interest for the treatment of erbb-2 gene over-expressing tumors, for which we have shown previously that combination treatment with both mAbs exerted synergistic effects on tumor inhibition in mice (13) . In this study, we describe novel cyclic peptides specific for the mAbs L-26 and N-12 by screening a random 12-mer phage display library. We found that the phage-displayed peptides were specific to their corresponding mAbs and no cross-reactivity was found (Fig. 2) . When synthetically manufactured solid phase recognition of cyclic peptides was especially detected when coupled to a carrier protein (KLH), probably due to the better immobilizing properties of the KLH molecule as compared with the unconjugated-free cyclic peptides. Peptides displayed as MAP with a dendrimeric structure were detectable but not the unconjugated-free linear peptides alone. Also here, MAP linear dendrimeric peptides are larger and thus exposure may have been improved as when peptides were used alone. In synthetically manufactured peptides, minor cross-reactivity was observed only for two of the peptides, N-12-1 and L-26-19 (Fig. 6 ).
Our sequence analyses of phage inserts found no sequence homology between the erbb-2 gene protein and the peptide mimotopes. Conceivably, conformational mimicry is the underlying mechanism for mAb specificity. In the pool of peptides specific for the mAbs L-26 or N-12, we repetitively sequenced identical peptides (Table 1) . Repetitive sequencing results could indicate growth advantage of bacteria infected with the phage-displayed peptides of a particular sequence. More likely, it represents a multiple selection event by the mAbs because identical amino acid sequences were encoded by different nucleotide sequences. For example, the peptide CILPSC was disclosed by two different nucleotide sequences. We also found peptides <12 amino acids (Table 1) , a phenomenon likely caused by the loss of amino acids during the synthesis of the phage library. Loss of amino acids during the amplification step seems unlikely because the short peptides reacted well with the mAbs in a specificity assay (Fig. 2) .
Earlier works on mimotope generation showed conserved amino acid motifs in phage-displayed peptides specific for a given mAb (32) . Within the two groups of peptides specific for L-26 and N-12 mAbs, we found no conserved motifs but computational analysis of the pool of peptides identified differences in physico-chemical properties between the two groups. Sequence alignment of peptides revealed a higher proportion of polar residues in peptides specific to N-12 mAb and groups of hydrophobic residues mainly at the N-terminal side in peptides specific to L-26 mAb (Fig. 1 ). These differences, along with the fact that L-26 and N-12 mAbs have synergistic functional effects are consistent with the observation that different epitopes are recognized by the mAbs on the surface of erbb-2 gene (13) .
It is notable that no experimental epitope mapping has been performed for L-26 mAb, yet functional studies using this mAb showed an influence on the heterodimerization of erbb-2 gene with other ErbB family members (17) . According to our computational prediction the epitope for L-26 localizes to domain IV (Fig. 8A, top) . Confirmation of domain IV as the likely site for the L-26 epitope came from another algorithm mapping the single peptides L-26-19 and L-26-24 again to the same site (Fig. 8A, bottom) . Interestingly, the predicted epitope overlapped the domain where Trastuzumab binds (41) , underlining the therapeutic potential of the L-26 mAb. Unlike for L-26 mAb, epitope mapping was carried out previously for N-12 mAb by an experimental approach. In this study, the N-12 epitope was localized to domain IV (residues 531-586) (27) . Yet, the epitope mapping for N-12 in this study was incomplete. This could be due to the methodological approach using antisera against N-12-specific mimotopes that originated from DNA fragments (100-300 bp) of the erbb-2 gene extracellular domain. Fragments of this length present tertiary structures that might differ from the natural erbb-2 gene protein. Indeed, screening with the mAb L-26 in this study did not result in positive clones, possibly due to epitopes that are far apart (>100 amino acids). In addition, epitope mapping for N-12 on the erbb-2 gene protein using these antisera was carried out with 15-mer-fragmented linear peptide sequences of the erbb-2 gene extracellular domain. In our work, analysis of the pool of N-12-specific peptides using the algorithm Mapitope suggested one epitope for N-12 (epitope 3 in Generation of erbb-2 gene-specific peptide mimotopes 399 domain IV) overlapping the experimentally approximated site (Fig. 8B) (27) . However, the other possible epitopes predicted by using the pool of peptides specific for N-12 localize to different sites (Fig. 8B, top) and none of the epitopes overlaps the sites that were predicted for the single epitopes N-12-1 and N-12-2.
Throughout this study, we observed that phage-displayed cyclic peptides or synthetic cyclic peptides (alone or coupled to KLH) were superior to their linear counterparts (alone or as MAP conjugates) in inhibiting mAb binding to the surface of erbb-2 gene-expressing BT474 or N87 cells (Figs 3 and 5 and data not shown). We were unable to achieve inhibition of mAb binding to the surface of BT474 cells whether we used linear peptides alone or peptides in the context of MAP dendrimeric peptides (data not shown and Fig. 5 ). Interestingly, even though no inhibition of mAb binding was observed, linear MAPs were detected by the mAbs L-26 or N-12 on the solid phase (Fig. 6 ). An earlier work in our lab showed the inhibition of L-26 mAb by a linear peptide to a monolayer of erbb-2 gene over-expressing cells. In this study, a 15-mer linear peptide was used. The same peptide in its cyclic form showed weaker ability to inhibit L-26 binding. Inhibition of L-26 binding by the linear peptide could be due to potential turns in the longer 15-mer sequence. Cyclization of the 15-mer peptide may have led to a conformational change such that the mimetic property of this peptide was almost abolished (26) .
Previous studies show that immunization with whole phages displaying the mimotopes initiated specific immune responses to disease-associated antigens, such as experiments performed in animal models of hepatitis B and C (46, 47) , allergy (48, 49) , experimental autoimmune encephalomyelitis (50), Alzheimer's disease (51) and breast cancer (25) . It is interesting that the immune responses following immunization with phage-displayed peptides or KLH-coupled peptides have been shown to be comparable. Specifically, the expression of Th1 type cytokines IFN-c, IL-2 and IL-12 was comparable in mice Generation of erbb-2 gene-specific peptide mimotopes 401 following phage-displayed or KLH-coupled peptide immunization. The expression of the T h 2 type cytokine IL-10 was similar, whereas IL-4 was not detected. Thus, peptides displayed by the phage may be a simple and less costly possibility for the production of a vaccine (52) . To date, several studies have investigated the possibility to vaccinate with erbb-2 gene and ErbB-1 mimotopes (25, 28, 29, 31) . In these studies, whole phage-displayed and synthetic mimotopes inhibited binding of the anti-erbb-2 gene and anti-ErbB-1 mAbs Trastuzumab and Cetuximab to the surface of erbb-2 gene-and ErbB-1-expressing cells, respectively (28, 31) . Antisera generated in the course of immunization experiments showed some specificity against erbb-2 gene and ErbB-1 (25, 28, 29, 31) and anti-tumorigenic activities in vitro (28, 31) and in vivo (29) . In the present study, we set out to immunize mice using whole phages displaying the selected mimotopes. However, this route of immunization was limited by toxicity, even though our phage preparation was sterile and prepared as described previously (51) . We then immunized mice with synthetic cyclic peptides coupled to KLH. Sera from mice immunized with the cyclic KLH-coupled peptides L-26-19 and L-26-24 showed higher reactivity toward ErbB-2-expressing BT474 cells as compared with pre-immune sera. Immunization with the N-12-1 peptide resulted in specific antisera although their reactivity to BT474 cells was lower than that of antisera to L-26-19 and L-26-24 (Fig. 7) . These results were consistent with the mAb inhibition experiments, in which cyclic and KLH-cyclic N-12-1 showed smaller effects as compared with L-26-19 or L-26-24.
Recognition of MAP peptides N-12-1 and L-26-19 on a solid phase persuaded us to immunize animals with the MAPs (Fig. 6 ). MAPs are characterized by a dendrimeric structure, and in comparison with the core matrix and the peptide monomers that do not show any structure, MAPs demonstrate increased helical structure and thus potentially higher immunogenicity (53) (54) (55) (56) . Yet, neither with linear peptides alone nor with linear peptides in a dendrimeric structure, in the context of MAPs, we were able to achieve inhibition of mAb binding to the surface of erbb-2 gene-expressing cells (data not shown and In summary, our study identified peptides specific to two non-competitory mAbs that act synergistically when used in combination in a mouse model of cancer (9) . If confirmed and enhanced, the peptides may serve as a starting point for the development of a vaccine active against erbb-2 gene-over-expressing tumors of breast, gastric and other tissues of origin. 
